The Potential of FOXP3 in Predicting Survival and Treatment Response in Breast Cancer

References

• Lei S, Zheng R, Zhang S, et al. Global patterns of breast cancer incidence and mortality: a population-based cancer registry data analysis from 2000 to 2020. Cancer Commun. 2021;41(11):1183–1194. doi:10.1002/cac2.12207
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Perez EA, Barrios C, Eiermann W, et al. Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase III MARIANNE Study. J Clin Oncol. 2017;35(2):141–148. doi:10.1200/JCO.2016.67.4887
   PubMed Web of Science ®Google Scholar
• Yi J, Chen S, Yi P, et al. Pyrotinib sensitizes 5-fluorouracil-resistant HER2(+) breast cancer cells to 5-fluorouracil. Oncol Res. 2020;28(5):519–531. doi:10.3727/096504020X15960154585410
   PubMed Web of Science ®Google Scholar
• Zeng J, Yi J, Tan S, et al. GPI: an indicator for immune infiltrates and prognosis of human breast cancer from a comprehensive analysis. Front Endocrinol. 2022;13:995972. doi:10.3389/fendo.2022.995972
   PubMed Web of Science ®Google Scholar
• Yi J, Tan S, Zeng Y, et al. Comprehensive analysis of prognostic and immune infiltrates for FOXPs transcription factors in human breast cancer. Sci Rep. 2022;12(1):8896. doi:10.1038/s41598-022-12954-3
   PubMed Web of Science ®Google Scholar
• Beyer M, Schultze JL. Regulatory T cells in cancer. Blood. 2006;108(3):804–811. doi:10.1182/blood-2006-02-002774
   PubMed Web of Science ®Google Scholar
• Jackson BC, Carpenter C, Nebert DW, Vasiliou V. Update of human and mouse forkhead box (FOX) gene families. Hum Genomics. 2010;4(5):345–352. doi:10.1186/1479-7364-4-5-345
   PubMedGoogle Scholar
• Wing JB, Tanaka A, Sakaguchi S. Human FOXP3(+) regulatory T cell heterogeneity and function in autoimmunity and cancer. Immunity. 2019;50(2):302–316. doi:10.1016/j.immuni.2019.01.020
   PubMed Web of Science ®Google Scholar
• Carvalho MI, Pires I, Prada J, Gregório H, Lobo L, Queiroga FL. Intratumoral FoxP3 expression is associated with angiogenesis and prognosis in malignant canine mammary tumors. Vet Immunol Immunopathol. 2016;178:1–9. doi:10.1016/j.vetimm.2016.06.006
   PubMed Web of Science ®Google Scholar
• Gong Z, Jia H, Xue L, et al. The emerging role of transcription factor FOXP3 in thyroid cancer. Rev Endocr Metab Disord. 2022;23(3):421–429. doi:10.1007/s11154-021-09684-8
   PubMed Web of Science ®Google Scholar
• Lal G, Bromberg JS. Epigenetic mechanisms of regulation of Foxp3 expression. Blood. 2009;114(18):3727–3735. doi:10.1182/blood-2009-05-219584
   PubMed Web of Science ®Google Scholar
• Ohara M, Yamaguchi Y, Matsuura K, Murakami S, Arihiro K, Okada M. Possible involvement of regulatory T cells in tumor onset and progression in primary breast cancer. Cancer Immunol Immunother. 2009;58(3):441–447. doi:10.1007/s00262-008-0570-x
   PubMed Web of Science ®Google Scholar
• Jørgensen N, Hviid T, Nielsen LB, et al. Tumour-infiltrating CD4-, CD8- and FOXP3-positive immune cells as predictive markers of mortality in BRCA1- and BRCA2-associated breast cancer. Br J Cancer. 2021;125(10):1388–1398. doi:10.1038/s41416-021-01514-7
   PubMed Web of Science ®Google Scholar
• Liu C, Han J, Li X, et al. FOXP3 inhibits the metastasis of breast cancer by downregulating the expression of MTA1. Front Oncol. 2021;11:656190. doi:10.3389/fonc.2021.656190
   PubMed Web of Science ®Google Scholar
• Attias M, Al-Aubodah T, Piccirillo CA. Mechanisms of human FoxP3(+) T(reg) cell development and function in health and disease. Clin Exp Immunol. 2019;197(1):36–51. doi:10.1111/cei.13290
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–e110. doi:10.1158/0008-5472.CAN-17-0307
   PubMed Web of Science ®Google Scholar
• Győrffy B, Surowiak P, Budczies J, Lánczky A, Chellappan SP. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One. 2013;8(12):e82241. doi:10.1371/journal.pone.0082241
   PubMed Web of Science ®Google Scholar
• Nagy Á, Lánczky A, Menyhárt O, Győrffy B. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep. 2018;8(1):9227. doi:10.1038/s41598-018-27521-y
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607–D613. doi:10.1093/nar/gky1131
   PubMed Web of Science ®Google Scholar
• Warde-Farley D, Donaldson SL, Comes O, et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. 2010;38(Web Server issue):W214–W220. doi:10.1093/nar/gkq537
   PubMed Web of Science ®Google Scholar
• Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–287. doi:10.1089/omi.2011.0118
   PubMed Web of Science ®Google Scholar
• Hnzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-Seq data. BMC Bioinformatics. 2013;14(1):7. doi:10.1186/1471-2105-14-7
   PubMedGoogle Scholar
• Gabriela B, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39(4):782–795. doi:10.1016/j.immuni.2013.10.003
   PubMed Web of Science ®Google Scholar
• Pinato DJ, Murray SM, Forner A, et al. Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy. J Immunother Cancer. 2021;9(9):e003311. doi:10.1136/jitc-2021-003311
   PubMed Web of Science ®Google Scholar
• Somasundaram R, Connelly T, Choi R, et al. Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy. Nat Commun. 2021;12(1):346. doi:10.1038/s41467-020-20600-7
   PubMed Web of Science ®Google Scholar
• Masuda T, Tanaka N, Takamatsu K, et al. Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer. J Immunother Cancer. 2022;10(3):1.
   Web of Science ®Google Scholar
• Lequerica-Fernández P, Suárez-Canto J, Rodriguez-Santamarta T, et al. Prognostic relevance of CD4(+), CD8(+) and FOXP3(+) TILs in oral squamous cell carcinoma and correlations with PD-L1 and cancer stem cell markers. Biomedicines. 2021;9(6):1.
   Web of Science ®Google Scholar
• Kaur HB, Vidotto T, Mendes AA, et al. Association between pathogenic germline mutations in BRCA2 and ATM and tumor-infiltrating lymphocytes in primary prostate cancer. Cancer Immunol Immunother. 2022;71(4):943–951. doi:10.1007/s00262-021-03050-y
   PubMed Web of Science ®Google Scholar
• Laissue P. The forkhead-box family of transcription factors: key molecular players in colorectal cancer pathogenesis. Mol Cancer. 2019;18(1):5. doi:10.1186/s12943-019-0938-x
   PubMedGoogle Scholar
• Lu L, Barbi J, Pan F. The regulation of immune tolerance by FOXP3. Nat Rev Immunol. 2017;17(11):703–717.
   PubMed Web of Science ®Google Scholar
• Zuo T, Wang L, Morrison C, et al. FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell. 2007;129(7):1275–1286. doi:10.1016/j.cell.2007.04.034
   PubMed Web of Science ®Google Scholar
• Zuo T, Liu R, Zhang H, et al. FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2. J Clin Invest. 2007;117(12):3765–3773. doi:10.1172/JCI32538
   PubMed Web of Science ®Google Scholar
• Merlo A, Casalini P, Carcangiu ML, et al. FOXP3 expression and overall survival in breast cancer. J Clin Oncol. 2009;27(11):1746–1752. doi:10.1200/JCO.2008.17.9036
   PubMed Web of Science ®Google Scholar
• Wang D, Huang S, Yuan X, et al. The regulation of the Treg/Th17 balance by mesenchymal stem cells in human systemic lupus erythematosus. Cell Mol Immunol. 2017;14(5):423–431. doi:10.1038/cmi.2015.89
   PubMed Web of Science ®Google Scholar
• Du R, Zhao H, Yan F, Li H. IL-17+Foxp3+ T cells: an intermediate differentiation stage between Th17 cells and regulatory T cells. J Leukoc Biol. 2014;96(1):39–48. doi:10.1189/jlb.1RU0114-010RR
   PubMed Web of Science ®Google Scholar
• West NR, Kost SE, Martin SD, et al. Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer. Br J Cancer. 2013;108(1):155–162. doi:10.1038/bjc.2012.524
   PubMed Web of Science ®Google Scholar
• McHugh RS, Whitters MJ, Piccirillo CA, et al. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity. 2002;16(2):311–323. doi:10.1016/S1074-7613(02)00280-7
   PubMed Web of Science ®Google Scholar
• Chen X, Du Y, Lin X, Qian Y, Zhou T, Huang Z. CD4+CD25+ regulatory T cells in tumor immunity. Int Immunopharmacol. 2016;34:244–249. doi:10.1016/j.intimp.2016.03.009
   PubMed Web of Science ®Google Scholar
• Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol. 2007;8(12):1353–1362. doi:10.1038/ni1536
   PubMed Web of Science ®Google Scholar
• Recouvreux MS, Grasso EN, Echeverria PC, et al. RUNX1 and FOXP3 interplay regulates expression of breast cancer related genes. Oncotarget. 2016;7(6):6552–6565. doi:10.18632/oncotarget.6771
   PubMedGoogle Scholar
• Liu Y, Zheng P. FOXP3 and breast cancer: implications for therapy and diagnosis. Pharmacogenomics. 2007;8(11):1485–1487. doi:10.2217/14622416.8.11.1485
   PubMed Web of Science ®Google Scholar
• Horlock C, Stott B, Dyson PJ, et al. The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer. Br J Cancer. 2009;100(7):1061–1067. doi:10.1038/sj.bjc.6604963
   PubMed Web of Science ®Google Scholar
• Seo AN, Lee HJ, Kim EJ, et al. Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer. 2013;109(10):2705–2713. doi:10.1038/bjc.2013.634
   PubMed Web of Science ®Google Scholar
• Oda N, Shimazu K, Naoi Y, et al. Intratumoral regulatory T cells as an independent predictive factor for pathological complete response to neoadjuvant paclitaxel followed by 5-FU/epirubicin/cyclophosphamide in breast cancer patients. Breast Cancer Res Treat. 2012;136(1):107–116. doi:10.1007/s10549-012-2245-8
   PubMed Web of Science ®Google Scholar